Q3-osavuosiraportti
10 päivää sitten‧1 t 9 min
3,75 DKK/osake
Viimeisin osinko
3,66 %Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
1 871 502
Myynti
Määrä
1 794 608
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 43 | - | - | ||
| 2 660 | - | - | ||
| 109 | - | - | ||
| 30 | - | - | ||
| 61 | - | - |
Ylin
314,95VWAP
Alin
307,85VaihtoMäärä
1 605,3 5 165 142
VWAP
Ylin
314,95Alin
307,85VaihtoMäärä
1 605,3 5 165 142
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Ylimääräinen yhtiökokous | 14.11. | |
| 2025 Q3-osavuosiraportti | 5.11. | |
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Q2-osavuosiraportti | 6.8. | |
| 2025 Q1-osavuosiraportti | 7.5. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·6 t sittenIt's a paradox that so many hate the NOVO stock due to self-ignorance, where one bought at 20x FPE and thought the stock was cheap. Also, when the price falls by 1/3, it was then actually "super expensive" and when FPE reaches 10 and dividend is around 5%, then it is again cheap, just much cheaper than before. Even if you made a good long-term investment that you are no longer as optimistic about, the "case" is relatively (EX competition and market development) the same even if the price is not. If you thought 500 DKK was a good price, then 350 is a fantastic price! The people here just lack some balls to stick with it or worse, they have FOMO because they are not surfing the AI wave, hahaha.
·10 t sittenguys and gals. find out if you are traders or investors.. have tried sitting with a large profit and failing by not looking at trend patterns, thought I was smarter than the market, but I wasn't and am not today. Novo is a solid fundamentally strong company which (with high probability will rise again if one has 3-5 years), adjusts to the new market demand new competitors etc. will Novo go bankrupt?, I don't think so, so is it smarter to just buy when it's far down when there's a bloodbath? 75-76000 employees plus minus what they end up with looks to me like a pretty solid company that still makes a lot of money compared to companies that only have hopeful products. Yes they have lost market shares Apple did too. market value? price targets from banks sitting and waiting for the price to fall so they can buy cheap? analyses that show this and that. yes they have competition- yes they are set back- yes people have lost a lot of money as investors- but will Novo come back in the long run? I really think the Danish 'folkeaktie' (people's stock) which isn't so popular anymore after all the layoffs and talk from this and that will come back. especially because it's just talk. who really knows what will happen in the future analysts etc.. One thing we all know. a cycle in life has ups and downs. kindly the dumb craftsman who also has Novo shares, and lost on them but holds.
10 t sitten10 t sittenTäällä on taistelu ”oman” ja amerikkalaisen osakkeen taistelun paremmuudesta. Et voi vaikuttaa osakkeiden kurssiin, ellet osta sadoilla miljoonilla. Miksi siis tuhlaat rahaa mahdolliseen putoavan puukkoon? Vain siksi että se on pohjoismaalainen? 😂·9 t sittenIt is correct that individuals do not move the market alone, but that does not mean that investing in Nordic stocks is a waste of money or that buying shares is catching a falling knife. It is clear that your frustration colors your judgment when you choose to disparage investments solely based on their geographical origin. I do not only own one stock like Novo Nordisk, but have a broad and balanced portfolio, respectively, in finance, Saab, Chemometec NKT, Novo and NTG, which includes both Danish and foreign stocks.·8 t sitten · MuokattuIt's fine that you have your own opinion, but that doesn't change the fact that debate about the stock market is about knowledge and analysis - not about showing off your portfolio. I have been in the stock market for 30 years - investing is about understanding the fundamental conditions behind the companies, not about who owns what. I therefore prefer to discuss financial statements, market outlooks and strategy rather than personal portfolios. By the way, you can read about my previous posts regarding Chemometec, NKT, NTG, GN Store Nord and many other companies on the platform.
·11 t sittenConsidering buying the American stock instead of the Danish one next time I top up, it seems that the Americans control both Novo's closing price and thereby also the opening price the day after. In short, it clearly has more power.
·9 t sittenAnd if, and I write if, their product also has a positive impact on ALZ, then Eli also has, it is fundamentally almost the same they sell, so it won't only be Novo standing with the golden palms, but several others..
9 t sitten · Muokattu9 t sitten · MuokattuEVOKE is focused trials with the semaglutide GLP-1 receptor agonist. It could very likely be that Eli also could prove a similar effect but they haven't announced any work on it so at best they will get a boost on that hope. They won't be able to claim it via clinical trial at least until they do the leg work.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
10 päivää sitten‧1 t 9 min
3,75 DKK/osake
Viimeisin osinko
3,66 %Tuotto/v
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sittenIt's a paradox that so many hate the NOVO stock due to self-ignorance, where one bought at 20x FPE and thought the stock was cheap. Also, when the price falls by 1/3, it was then actually "super expensive" and when FPE reaches 10 and dividend is around 5%, then it is again cheap, just much cheaper than before. Even if you made a good long-term investment that you are no longer as optimistic about, the "case" is relatively (EX competition and market development) the same even if the price is not. If you thought 500 DKK was a good price, then 350 is a fantastic price! The people here just lack some balls to stick with it or worse, they have FOMO because they are not surfing the AI wave, hahaha.
- ·10 t sittenguys and gals. find out if you are traders or investors.. have tried sitting with a large profit and failing by not looking at trend patterns, thought I was smarter than the market, but I wasn't and am not today. Novo is a solid fundamentally strong company which (with high probability will rise again if one has 3-5 years), adjusts to the new market demand new competitors etc. will Novo go bankrupt?, I don't think so, so is it smarter to just buy when it's far down when there's a bloodbath? 75-76000 employees plus minus what they end up with looks to me like a pretty solid company that still makes a lot of money compared to companies that only have hopeful products. Yes they have lost market shares Apple did too. market value? price targets from banks sitting and waiting for the price to fall so they can buy cheap? analyses that show this and that. yes they have competition- yes they are set back- yes people have lost a lot of money as investors- but will Novo come back in the long run? I really think the Danish 'folkeaktie' (people's stock) which isn't so popular anymore after all the layoffs and talk from this and that will come back. especially because it's just talk. who really knows what will happen in the future analysts etc.. One thing we all know. a cycle in life has ups and downs. kindly the dumb craftsman who also has Novo shares, and lost on them but holds.
- 10 t sitten10 t sittenTäällä on taistelu ”oman” ja amerikkalaisen osakkeen taistelun paremmuudesta. Et voi vaikuttaa osakkeiden kurssiin, ellet osta sadoilla miljoonilla. Miksi siis tuhlaat rahaa mahdolliseen putoavan puukkoon? Vain siksi että se on pohjoismaalainen? 😂·9 t sittenIt is correct that individuals do not move the market alone, but that does not mean that investing in Nordic stocks is a waste of money or that buying shares is catching a falling knife. It is clear that your frustration colors your judgment when you choose to disparage investments solely based on their geographical origin. I do not only own one stock like Novo Nordisk, but have a broad and balanced portfolio, respectively, in finance, Saab, Chemometec NKT, Novo and NTG, which includes both Danish and foreign stocks.·8 t sitten · MuokattuIt's fine that you have your own opinion, but that doesn't change the fact that debate about the stock market is about knowledge and analysis - not about showing off your portfolio. I have been in the stock market for 30 years - investing is about understanding the fundamental conditions behind the companies, not about who owns what. I therefore prefer to discuss financial statements, market outlooks and strategy rather than personal portfolios. By the way, you can read about my previous posts regarding Chemometec, NKT, NTG, GN Store Nord and many other companies on the platform.
- ·11 t sittenConsidering buying the American stock instead of the Danish one next time I top up, it seems that the Americans control both Novo's closing price and thereby also the opening price the day after. In short, it clearly has more power.·9 t sittenAnd if, and I write if, their product also has a positive impact on ALZ, then Eli also has, it is fundamentally almost the same they sell, so it won't only be Novo standing with the golden palms, but several others..9 t sitten · Muokattu9 t sitten · MuokattuEVOKE is focused trials with the semaglutide GLP-1 receptor agonist. It could very likely be that Eli also could prove a similar effect but they haven't announced any work on it so at best they will get a boost on that hope. They won't be able to claim it via clinical trial at least until they do the leg work.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
1 871 502
Myynti
Määrä
1 794 608
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 43 | - | - | ||
| 2 660 | - | - | ||
| 109 | - | - | ||
| 30 | - | - | ||
| 61 | - | - |
Ylin
314,95VWAP
Alin
307,85VaihtoMäärä
1 605,3 5 165 142
VWAP
Ylin
314,95Alin
307,85VaihtoMäärä
1 605,3 5 165 142
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Ylimääräinen yhtiökokous | 14.11. | |
| 2025 Q3-osavuosiraportti | 5.11. | |
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Q2-osavuosiraportti | 6.8. | |
| 2025 Q1-osavuosiraportti | 7.5. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
10 päivää sitten‧1 t 9 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Ylimääräinen yhtiökokous | 14.11. | |
| 2025 Q3-osavuosiraportti | 5.11. | |
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Q2-osavuosiraportti | 6.8. | |
| 2025 Q1-osavuosiraportti | 7.5. |
Datan lähde: Millistream, Quartr
3,75 DKK/osake
Viimeisin osinko
3,66 %Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sittenIt's a paradox that so many hate the NOVO stock due to self-ignorance, where one bought at 20x FPE and thought the stock was cheap. Also, when the price falls by 1/3, it was then actually "super expensive" and when FPE reaches 10 and dividend is around 5%, then it is again cheap, just much cheaper than before. Even if you made a good long-term investment that you are no longer as optimistic about, the "case" is relatively (EX competition and market development) the same even if the price is not. If you thought 500 DKK was a good price, then 350 is a fantastic price! The people here just lack some balls to stick with it or worse, they have FOMO because they are not surfing the AI wave, hahaha.
- ·10 t sittenguys and gals. find out if you are traders or investors.. have tried sitting with a large profit and failing by not looking at trend patterns, thought I was smarter than the market, but I wasn't and am not today. Novo is a solid fundamentally strong company which (with high probability will rise again if one has 3-5 years), adjusts to the new market demand new competitors etc. will Novo go bankrupt?, I don't think so, so is it smarter to just buy when it's far down when there's a bloodbath? 75-76000 employees plus minus what they end up with looks to me like a pretty solid company that still makes a lot of money compared to companies that only have hopeful products. Yes they have lost market shares Apple did too. market value? price targets from banks sitting and waiting for the price to fall so they can buy cheap? analyses that show this and that. yes they have competition- yes they are set back- yes people have lost a lot of money as investors- but will Novo come back in the long run? I really think the Danish 'folkeaktie' (people's stock) which isn't so popular anymore after all the layoffs and talk from this and that will come back. especially because it's just talk. who really knows what will happen in the future analysts etc.. One thing we all know. a cycle in life has ups and downs. kindly the dumb craftsman who also has Novo shares, and lost on them but holds.
- 10 t sitten10 t sittenTäällä on taistelu ”oman” ja amerikkalaisen osakkeen taistelun paremmuudesta. Et voi vaikuttaa osakkeiden kurssiin, ellet osta sadoilla miljoonilla. Miksi siis tuhlaat rahaa mahdolliseen putoavan puukkoon? Vain siksi että se on pohjoismaalainen? 😂·9 t sittenIt is correct that individuals do not move the market alone, but that does not mean that investing in Nordic stocks is a waste of money or that buying shares is catching a falling knife. It is clear that your frustration colors your judgment when you choose to disparage investments solely based on their geographical origin. I do not only own one stock like Novo Nordisk, but have a broad and balanced portfolio, respectively, in finance, Saab, Chemometec NKT, Novo and NTG, which includes both Danish and foreign stocks.·8 t sitten · MuokattuIt's fine that you have your own opinion, but that doesn't change the fact that debate about the stock market is about knowledge and analysis - not about showing off your portfolio. I have been in the stock market for 30 years - investing is about understanding the fundamental conditions behind the companies, not about who owns what. I therefore prefer to discuss financial statements, market outlooks and strategy rather than personal portfolios. By the way, you can read about my previous posts regarding Chemometec, NKT, NTG, GN Store Nord and many other companies on the platform.
- ·11 t sittenConsidering buying the American stock instead of the Danish one next time I top up, it seems that the Americans control both Novo's closing price and thereby also the opening price the day after. In short, it clearly has more power.·9 t sittenAnd if, and I write if, their product also has a positive impact on ALZ, then Eli also has, it is fundamentally almost the same they sell, so it won't only be Novo standing with the golden palms, but several others..9 t sitten · Muokattu9 t sitten · MuokattuEVOKE is focused trials with the semaglutide GLP-1 receptor agonist. It could very likely be that Eli also could prove a similar effect but they haven't announced any work on it so at best they will get a boost on that hope. They won't be able to claim it via clinical trial at least until they do the leg work.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
1 871 502
Myynti
Määrä
1 794 608
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 43 | - | - | ||
| 2 660 | - | - | ||
| 109 | - | - | ||
| 30 | - | - | ||
| 61 | - | - |
Ylin
314,95VWAP
Alin
307,85VaihtoMäärä
1 605,3 5 165 142
VWAP
Ylin
314,95Alin
307,85VaihtoMäärä
1 605,3 5 165 142
Välittäjätilasto
Dataa ei löytynyt